"Can we just use REDCap for this?" may be the single most frequently asked technology question in academic clinical research — and it deserves a better answer than either reflexive yes or reflexive no. The honest answer depends on the study, the funding, and the compliance context. This guide lays out the three broad options that recur in this decision, what each is genuinely good at, and a framework for choosing.

What REDCap is

REDCap (Research Electronic Data Capture) is a web-based data capture platform developed at Vanderbilt University, first described by Harris and colleagues in 2009 as a metadata-driven approach to building research databases without programmers [1]. Its distribution model is unusual and central to understanding it: REDCap is not sold. Vanderbilt licenses it at no charge to nonprofit institutional partners, each of which hosts and administers its own instance; the consortium spans thousands of institutions worldwide [2]. (A separate commercial offering, REDCap Cloud, provides hosted services under its own terms — it is a distinct product and company, and worth distinguishing in any evaluation.)

For a researcher at a member institution, the practical experience is: request a project, build forms yourself in a browser, deploy surveys or data entry, and export data — often within days, at no direct software cost to the study.

Where REDCap excels

REDCap's strengths are documented by its sheer prevalence in academic research and are consistent with its design goals [1][2]:

  • Investigator-initiated studies — a coordinator or investigator can build a workable database without a data management department.
  • Surveys and participant-reported data — built-in survey distribution, scheduling, and longitudinal follow-up suit cohort studies and repeated-measures designs.
  • Registries and observational research — flexible eCRF design without per-study build costs makes long-running registries economically viable.
  • Cost and speed — for a funded academic study with a modest data management budget, "already licensed, already hosted, already trained" is a real advantage, and one our funding guide puts in context.

REDCap's boundaries

None of these are defects; they are consequences of the model.

  • Regulated trials. Studies conducted under FDA regulations bring 21 CFR Part 11 expectations for electronic records and signatures [3][4]. REDCap includes relevant technical features (audit trails, e-signature options), but Part 11 readiness is a property of the installation and its operating procedures — hosting, validation, SOPs, training — not of the software alone. Whether a given institutional instance is appropriate for a given regulated study is a determination that institution's compliance function has to make and document. Some institutions do run validated instances for regulated work; many explicitly do not.
  • The support model. There is no vendor on the hook. Institutional REDCap teams vary from well-staffed cores to a fraction of one administrator's time, and study teams do much of the build themselves — which is empowering for simple studies and a risk for complex ones.
  • Complex trial operations. Sophisticated randomization schemes, trial supply management, integrated safety reconciliation, and submission-grade CDISC support are areas where purpose-built trial systems have invested far more deeply.

When commercial EDC fits

Commercial EDC systems — Castor, Medidata Rave, Medrio, OpenClinica, Oracle Clinical One, Veeva Clinical Data, and Zelta (formerly IBM Clinical Development) are among the products in this space — are built and sold for study-specific, often regulated, data capture. Their case is strongest when:

  • The study is a sponsored, regulated trial. Vendors supply validation documentation and maintain their systems against Part 11 and GCP expectations as a core part of the product [3][4].
  • Someone must be accountable. A contract puts a vendor on the hook for uptime, support, hosting, and change control — which sponsors and auditors can inspect.
  • Trial-specific machinery matters. Randomization, blinding, query management at scale, medical coding integration, and database lock workflows are first-class features rather than configurations.

The tradeoffs are equally real: per-study licensing and build costs, procurement timelines, and often a professional build process where the study team cannot simply change a form themselves.

When a configurable research platform fits

A third pattern serves institutions and networks rather than single studies: a platform configured to run many heterogeneous studies — registries, cohorts, investigator-initiated trials, multi-site collaborations — under one roof, with shared form libraries, multi-study management, and multi-site controls. Products positioned here (in our technology landscape, this includes offerings from vendors such as Castor, OpenClinica, QuesGen, and REDCap Cloud, among others) trade some of REDCap's zero-cost accessibility and some of study-specific EDC's per-trial depth for institutional consistency: common standards, common governance, and one place to answer "what studies do we have and what state is their data in?"

The fit is strongest for research organizations with a portfolio problem — many studies, varied designs, mixed compliance levels — and weakest for a single study that just needs a database.

The hybrid reality

In our assessment, the most accurate description of academic research institutions today is not "a REDCap shop" or "a commercial shop" but both, deliberately: REDCap for surveys, registries, and unregulated investigator-initiated work; commercial EDC (frequently chosen by the sponsor, not the site) for regulated trials; and sometimes a configurable platform for a specific portfolio. The practical questions then become governance ones — which studies go where, who decides, and how data moves between systems (data export, APIs and data import).

A decision framework

Work through three questions in order:

  1. Compliance context. Is the study under FDA regulations (an IND/IDE trial, or intended to support a marketing submission)? If yes, the system and its operating environment must satisfy Part 11 and GCP expectations [3][4] — which typically means a validated commercial system or a formally validated institutional instance, documented either way. If no, the field is wide open.
  2. Study type and complexity. Surveys, single-site cohorts, and registries sit comfortably in REDCap. Randomized, blinded, multi-site, or safety-intensive designs pull toward purpose-built trial systems. A portfolio of many studies pulls toward a platform approach.
  3. Funding and accountability. Who pays, and who answers for the system? A sponsor paying for a trial usually specifies or funds the EDC. A modest investigator grant may make institutional REDCap the only realistic option — a legitimate reason, best acknowledged openly. An institution funding infrastructure should weigh total cost across the portfolio, not per study.

If two answers conflict — a regulated study with no budget for a commercial system, say — that conflict is the finding: it is a conversation to have with the sponsor, funder, or institution before the build, not a gap to paper over.

Where to go next

Our technology directory classifies products by primary function — descriptively, never as a ranking — and Choosing an Electronic Data Capture System covers the evaluation process itself. For what the chosen system will actually have to do, see From Protocol to Database Lock.